Full Text View
Tabular View
No Study Results Posted
Related Studies
Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With Visceral Leishmaniasis
This study is not yet open for participant recruitment.
Study NCT00832208.   Last updated on January 29, 2009.
Information provided by Drugs for Neglected Diseases
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Visceral Leishmaniasis
Additional conditions recognized in this trial
Leishmaniasis
Leishmaniasis, Visceral
More general conditions related to this trial
Mastigophora Infections
Parasitic Diseases
Protozoan Infections
Sarcomastigophora Infections
Skin Diseases
Skin Diseases, Infectious
Skin Diseases, Parasitic
Interventions listed in this trial
Liposomal amphotericin B (Ambisome)
Additional drug interventions recognized in this trial
Abelcet
Amphotericin B
Liposomal amphotericin B
More general drug interventions related to this trial
Amebicides
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antifungal
Antifungal Agents
Antiparasitic Agents
Antiprotozoal Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Drugs for Neglected Diseases
Addis Ababa University


U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services